Neonatal Jaundice Treatment Device

$1.00

WhatsApp Order

A Neonatal Jaundice Treatment Device (phototherapy unit) is a Class II medical device that delivers therapeutic blue light (450-470 nm) to treat hyperbilirubinemia in newborns, preventing bilirubin-induced neurological damage (kernicterus). Available as overhead units (mobile stands with LED or fluorescent lamps), fiberoptic systems (Biliblanket) with illuminated pads placed against the infant’s skin, and combination systems for intensive therapy. Irradiance ranges from 10-50+ µW/cm²/nm at treatment distance. LED units offer specific wavelength output, minimal heat, long life (10,000-50,000 hours), and energy efficiency. Treatment indications follow AAP hour-specific nomograms based on gestational age, birth weight, postnatal age, and risk factors. Essential safety requirements include opaque eye shields to protect neonatal retinas, temperature monitoring to prevent hyperthermia, hydration maintenance, and regular irradiance verification. Used in hospital NICUs, newborn nurseries, and (select devices) home care settings for mild jaundice. Critical for preventing permanent neurological sequelae of untreated severe neonatal jaundice.

Categories: OBSTETRICS, GYNECOLOGY AND NEONATAL, PATIENT MONITORING AND LIFE SUPPORT Tags: Bili blanket, Bili Light, Hyperbilirubinemia Treatment, LED Phototherapy, Neonatal Jaundice Treatment, Neonatal Phototherapy, Newborn Jaundice, Phototherapy Unit

Description

Neonatal Jaundice Treatment Device

PRIMARY CLINICAL & DIAGNOSTIC USES

1. Phototherapy for Neonatal Hyperbilirubinemia

Primary Use: Delivers therapeutic light (typically in the blue spectrum, 430-490 nm) to convert bilirubin into water-soluble isomers that can be excreted without conjugation.
How it helps: For the neonatologist and pediatrician, it provides a non-invasive, highly effective tool to lower bilirubin levels by simply “rearranging” the molecule so the baby’s immature liver doesn’t have to process it. For the jaundiced newborn, this light acts like a key—transforming toxic, fat-soluble bilirubin into a harmless, water-soluble form that can be peed out, clearing the yellow color from their skin and protecting their developing brain.

2. Prevention of Kernicterus and Bilirubin-Induced Neurological Damage

Primary Use: Prevents accumulation of neurotoxic unconjugated bilirubin in the basal ganglia and brainstem, avoiding permanent neurological sequelae.
How it helps: For the clinical team, it is their primary weapon against one of the most preventable catastrophic outcomes in neonatology—permanent brain damage from untreated jaundice. For the infant and their future, timely phototherapy means protection against lifelong disabilities including hearing loss, movement disorders, and intellectual impairment, allowing them to reach their full developmental potential.

3. Management of Hemolytic Disease of the Newborn

Primary Use: Used in neonates with isoimmunization (ABO or Rh incompatibility), G6PD deficiency, or other hemolytic conditions causing rapid bilirubin rise.
How it helps: For the neonatologist managing these high-risk infants, intensive phototherapy buys critical time—slowing the rise of bilirubin while preparing for exchange transfusion if needed. For the baby whose blood type is incompatible with their mother’s, or who lacks critical enzymes, this aggressive light therapy can sometimes eliminate the need for a risky exchange transfusion entirely, or at least stabilize them until definitive treatment is ready.

4. Treatment of Breastfeeding-Associated Jaundice

Primary Use: Addresses exaggerated physiological jaundice in breastfed infants due to inadequate milk intake or breast milk factors.
How it helps: For the lactation consultant and pediatrician, it provides a medical bridge while they work on the root cause—improving feeding efficiency and milk transfer. For the breastfed infant, phototherapy keeps bilirubin levels safe while mother and baby work together to establish effective nursing, allowing breastfeeding to continue successfully without interruption for medical intervention.

5. Management of Preterm Infant Jaundice

Primary Use: Premature infants have immature hepatic conjugation and are at higher risk for severe hyperbilirubinemia at lower bilirubin levels.
How it helps: For the NICU team caring for preemies, phototherapy is initiated at much lower thresholds than in term babies, recognizing their extreme vulnerability. For the premature infant, whose liver is weeks or months away from functioning properly, early and intensive light therapy compensates for their immaturity, protecting their developing brain while they grow strong enough to handle bilirubin on their own.

6. Post-Exchange Transfusion Phototherapy

Primary Use: Following exchange transfusion, phototherapy is continued to prevent rebound hyperbilirubinemia and maintain safe bilirubin levels during recovery.
How it helps: For the neonatologist who has just performed an exchange transfusion, continued phototherapy ensures the baby doesn’t rebound to dangerous levels as bilirubin from tissues re-enters the bloodstream. For the infant who has undergone this major procedure, the lights provide a protective safety net during the vulnerable recovery period, allowing the team to monitor safely without rushing to repeat the exchange.

7. Home-Based Phototherapy for Mild to Moderate Jaundice

Primary Use: Some devices are designed for home use under medical supervision, allowing infants with stable jaundice to receive treatment at home.
How it helps: For the discharge planner and visiting nurse, home phototherapy reduces hospital length of stay and frees up NICU beds for sicker infants. For parents eager to bring their baby home, a home device means their newborn can receive necessary treatment while sleeping in their own nursery, feeding on demand, and bonding with family—without the stress and separation of prolonged hospitalization.

SECONDARY & SUPPORTIVE USES

1. Research and Clinical Studies: For the neonatal researcher, it enables investigation into bilirubin metabolism, optimal light wavelengths, and long-term outcomes of treated infants. For future generations of newborns, this research translates into more effective, safer phototherapy protocols.

2. Teaching and Training: For the neonatology educator, it is essential equipment for teaching the next generation of providers about jaundice management. For the trainee—whether medical student, resident, or nurse—hands-on experience with phototherapy devices builds competence in recognizing and treating one of the most common conditions in newborn medicine.

3. Quality Assurance Programs: For the hospital quality improvement team, standardized use of phototherapy devices helps track outcomes and reduce the incidence of severe hyperbilirubinemia. For every infant born in that hospital, these quality initiatives mean consistent, evidence-based care that protects them from preventable harm.

KEY PRODUCT FEATURES

1. BASIC IDENTIFICATION ATTRIBUTES

Product Type: Medical device delivering therapeutic light (typically blue spectrum) for treatment of neonatal hyperbilirubinemia.
Common Names: Phototherapy Unit, Neonatal Jaundice Treatment Device, Billi Light, Phototherapy Lamp, Biliblanket, Fiberoptic Phototherapy System, LED Phototherapy Unit.
Types of Phototherapy Devices:
- Conventional Phototherapy: Fluorescent or LED lamps positioned above the infant (overhead units).
- Intensive Phototherapy: Higher irradiance units (≥30 µW/cm²/nm) for rapid bilirubin reduction.
- Fiberoptic Phototherapy (Biliblanket): Light emitted through a fiberoptic pad placed directly against an infant's skin; allows continued skin-to-skin contact and breastfeeding during treatment.
- LED Phototherapy: Light-emitting diode arrays with specific blue wavelengths (450-470 nm optimal) for efficient bilirubin reduction with minimal heat.
- Multi-Light Systems: Combination of overhead and fiberoptic units for maximal irradiance.
Light Source Types:
- LED (Light-Emitting Diode): Most common modern source; specific blue wavelengths (450-470 nm); long life, minimal heat, energy efficient.
- Fluorescent (Special Blue): Traditional source; broader spectrum; generates more heat; shorter lamp life.
- Halogen/Tungsten: Older technology; less efficient; high heat output; largely obsolete.
- Fiberoptic: Light generated remotely and transmitted through fiber optic cable to illuminated pad.
Spectral Output: Peak wavelength typically 450-470 nm (blue spectrum optimal for bilirubin absorption).
Irradiance: Measured in µW/cm²/nm at skin level (typical range: 10-50+ µW/cm²/nm).
Treatment Surface Area: Size of illuminated area (varies by device type).

2. TECHNICAL & PERFORMANCE PROPERTIES

Peak Wavelength: 450-470 nm (optimal for bilirubin absorption). Narrow spectrum LEDs provide targeted therapy with minimal unnecessary light.
Irradiance Output: 10-50+ µW/cm²/nm at specified distance (intensive units ≥30 µW/cm²/nm).
Spectral Width: Half-peak bandwidth typically 20-40 nm (narrower is more efficient).
Treatment Area Coverage: Overhead units: 30-60 cm × 20-40 cm; Fiberoptic pads: 10-25 cm × 15-30 cm.
Irradiance Uniformity: ±20% variation across treatment areas (meets international standards).
Warm-Up Time: LED units: instant; Fluorescent: 1-5 minutes.
Lamp Life: LED: 10,000-50,000 hours; Fluorescent: 1,000-2,000 hours.
Heat Output: LED: minimal; Fluorescent: significant (requires ventilation).
Timer: Built-in hour meter for tracking lamp life and treatment duration.
Alarms: Some units include alarms for fan failure, lamp failure, or excessive temperature.
Adjustability: Height adjustment for overhead units; flexible positioning arms.

3. PHYSICAL & OPERATIONAL PROPERTIES

Overhead Phototherapy Units:
- Configuration: Mobile stand with adjustable height arm and lamp head.
- Lamp Head: Contains LED array or fluorescent lamps with reflector.
- Controls: On/off, timer, irradiance settings (if adjustable).
- Dimensions (Head): 30-60 cm × 20-40 cm.
- Height Range: Adjustable from 100-180 cm from floor.
- Casters: Locking casters for mobility and stability.
Fiberoptic Phototherapy Systems (Biliblanket):
- Light Source Console: Generates light; contains lamp and cooling fan.
- Fiberoptic Cable: Flexible cable transmitting light to pad.
- **Illuminated Pad/Pad: Flexible, washable pad emitting light; placed against infant's skin.
- Console Dimensions: 20-30 cm × 15-25 cm × 10-20 cm.
- Pad Dimensions: 10-25 cm × 15-30 cm.
- Weight: 3-8 kg (console).
LED Phototherapy Units:
- Configuration: Mobile or fixed; may be overhead or under-bed (bassinet) type.
- LED Array: Multiple high-intensity LEDs with specific wavelength.
- Cooling: Passive or fan-cooled; minimal heat output.
- Controls: Digital display, timer, irradiance adjustment.
Material: Medical-grade plastic housing; easy-clean surfaces.
Power Requirements: 100-240 VAC, 50/60 Hz.
Certifications: Complies with relevant medical device standards (IEC 60601-2-50 for phototherapy equipment).

4. SAFETY & COMPLIANCE ATTRIBUTES

Regulatory Status: Class II medical device requiring FDA 510(k) clearance; CE marked.
Clinical Standards: Complies with IEC 60601-2-50 (particular requirements for infant phototherapy equipment).
Optical Safety: UV emission must be minimal (<0.001 mW/cm²); blue light exposure within safe limits for neonatal retina (AAP guidelines).
Thermal Safety: Surface temperatures limited to prevent burns; overheating protection.
Electrical Safety: Compliant with IEC 60601-1 for medical electrical equipment.
Mechanical Safety: Stable base prevents tipping; secure cord management.
Irradiance Measurement: Built-in or accessory irradiance meter for verifying treatment dose.
Lamp Life Indicator: Hour meter or timer to track lamp replacement needs.
Eye Protection: Infants require eye shields (opaque patches) to protect retinas from intense light during treatment.
Skin Protection: Monitor for skin rash, hyperthermia, or dehydration during prolonged treatment.
Quality Management: Manufactured under ISO 13485 certified processes.

5. STORAGE & HANDLING ATTRIBUTES

Storage: Store in a clean, dry environment; protect from dust and physical damage.
Cleaning: Wipe with EPA-registered hospital disinfectant between patients; follow manufacturer instructions for fiberoptic pads (some are machine washable).
Lamp Replacement: Replace lamps per manufacturer schedule (hour meter tracks usage); use only specified lamps.
Filter Cleaning: Clean or replace air intake filters regularly to prevent overheating.
Fiberoptic Pad Care: Inspect for damage (dark spots, cracks); clean per manufacturer; replace if damaged.
Irradiance Verification: Regularly verify output with calibrated irradiance meter (per hospital protocol).
Calibration: Annual calibration verification recommended for irradiance measurement devices.
Inspection: Before each use, check for damaged cords, loose connections, cracked housings, and proper lamp operation.
Eye Shields: Ensure appropriate infant eye shields are available and in good condition.

6. LABORATORY & CLINICAL APPLICATIONS

Primary Application: Treatment of neonatal hyperbilirubinemia (jaundice) to prevent bilirubin-induced neurological damage.
Indications for Phototherapy (AAP Guidelines):
- Thresholds based on: Gestational age, birth weight, postnatal age (hours), and risk factors (hemolysis, sepsis, asphyxia, acidosis).
- Hour-Specific Nomograms: Treatment initiated when total serum bilirubin exceeds age-specific threshold (AAP nomogram).
- Risk Assessment: Higher-risk infants (hemolytic disease, preterm, sick) treated at lower bilirubin levels.
Phototherapy Techniques:
- Conventional: Single overhead unit; irradiance 8-12 µW/cm²/nm.
- Intensive: Multiple units or high-intensity LED; irradiance ≥30 µW/cm²/nm; for rapid bilirubin reduction.
- Double/Triple Phototherapy: Multiple units (overhead + fiberoptic) for maximum intensity.
- Fiberoptic: Allows continued skin-to-skin contact and breastfeeding; may be used alone for mild jaundice or combined with overhead for intensive treatment.
Treatment Monitoring:
- Serum Bilirubin: Measured every 4-24 hours depending on severity and response.
- Irradiance Measurement: Verify output at skin level with calibrated meter.
- Infant Monitoring: Temperature, hydration status, skin integrity, stool output.
- Duration: Continue until bilirubin falls to safe level (typically 2-4 mg/dL below treatment threshold).
Eye Protection: Apply opaque eye shields immediately upon starting phototherapy; monitor for proper positioning; remove for feeds and care (reapply).
Supportive Care: Ensure adequate hydration (may increase insensible water loss); monitor for loose stools; maintain thermoregulation.

SAFETY HANDLING PRECAUTIONS

1. SAFETY PRECAUTIONS

Eye Protection (MOST IMPORTANT): Always cover an infant's eyes with opaque shields during phototherapy. Ensure shields do not occlude nares. Check positioning frequently. Remove for feeding and parental bonding (reapply immediately).
Temperature Monitoring: Phototherapy can increase body temperature; monitor infant temperature regularly. Adjust incubator temperature or remove clothing as needed.
Hydration: Increased insensible water loss may occur; ensure adequate fluid intake; monitor urine output and weight.
Skin Integrity: Check skin under eye shields and phototherapy area for irritation or rash.
Lamp Distance: Maintain manufacturer-recommended distance from infant to achieve target irradiance while preventing overheating.
Irradiance Verification: Regularly measure output with calibrated meter; document readings.
Lamp Replacement: Replace lamps at recommended intervals; output decreases over time.
Electrical Safety: Keep cords away from water; use hospital-grade outlets; ensure proper grounding.
Parent Education: Explain purpose of treatment, need for eye protection, and importance of monitoring.
Contraindications: Direct hyperbilirubinemia (conjugated bilirubin elevation) is not treated with phototherapy (may cause bronze baby syndrome).

2. FIRST AID MEASURES

Eye Shield Displacement: Immediately reposition; ensure proper coverage; check eyes for irritation.
Overheating/Hyperthermia: Stop phototherapy; remove excess clothing; monitor temperature; notify physician.
Skin Rash/Irritation: Assess; may require modification of treatment (fiberoptic alternative); notify physician.
Lamp Failure: Replace lamp; have backup unit available; continue treatment with alternative device.
Power Failure: Use backup power source; have emergency protocol.

3. FIRE FIGHTING MEASURES

Flammability: Plastic components are combustible; electrical components pose fire risk.
Extinguishing Media: For electrical fire, use CO₂ or dry chemical (Class C) extinguisher.
Power Off: Disconnect power if safe to do so.
Evacuation: Evacuate infant if fire risk; follow NICU fire evacuation protocols.

Neonatal Jaundice Treatment Device

Neonatal Jaundice Treatment Device

PRIMARY CLINICAL & DIAGNOSTIC USES

1. Phototherapy for Neonatal Hyperbilirubinemia

Primary Use: Delivers therapeutic light (typically in the blue spectrum, 430-490 nm) to convert bilirubin into water-soluble isomers that can be excreted without conjugation.

2. Prevention of Kernicterus and Bilirubin-Induced Neurological Damage

Primary Use: Prevents accumulation of neurotoxic unconjugated bilirubin in the basal ganglia and brainstem, avoiding permanent neurological sequelae.

3. Management of Hemolytic Disease of the Newborn

Primary Use: Used in neonates with isoimmunization (ABO or Rh incompatibility), G6PD deficiency, or other hemolytic conditions causing rapid bilirubin rise.

4. Treatment of Breastfeeding-Associated Jaundice

Primary Use: Addresses exaggerated physiological jaundice in breastfed infants due to inadequate milk intake or breast milk factors.

5. Management of Preterm Infant Jaundice

Primary Use: Premature infants have immature hepatic conjugation and are at higher risk for severe hyperbilirubinemia at lower bilirubin levels.

6. Post-Exchange Transfusion Phototherapy

Primary Use: Following exchange transfusion, phototherapy is continued to prevent rebound hyperbilirubinemia and maintain safe bilirubin levels during recovery.

7. Home-Based Phototherapy for Mild to Moderate Jaundice

Primary Use: Some devices are designed for home use under medical supervision, allowing infants with stable jaundice to receive treatment at home.

SECONDARY & SUPPORTIVE USES

1. Research and Clinical Studies: For the neonatal researcher, it enables investigation into bilirubin metabolism, optimal light wavelengths, and long-term outcomes of treated infants. For future generations of newborns, this research translates into more effective, safer phototherapy protocols.

1. BASIC IDENTIFICATION ATTRIBUTES

Product Type: Medical device delivering therapeutic light (typically blue spectrum) for treatment of neonatal hyperbilirubinemia.

Common Names: Phototherapy Unit, Neonatal Jaundice Treatment Device, Billi Light, Phototherapy Lamp, Biliblanket, Fiberoptic Phototherapy System, LED Phototherapy Unit.

Types of Phototherapy Devices:

Conventional Phototherapy: Fluorescent or LED lamps positioned above the infant (overhead units).

Intensive Phototherapy: Higher irradiance units (≥30 µW/cm²/nm) for rapid bilirubin reduction.

Fiberoptic Phototherapy (Biliblanket): Light emitted through a fiberoptic pad placed directly against an infant's skin; allows continued skin-to-skin contact and breastfeeding during treatment.

LED Phototherapy: Light-emitting diode arrays with specific blue wavelengths (450-470 nm optimal) for efficient bilirubin reduction with minimal heat.

Multi-Light Systems: Combination of overhead and fiberoptic units for maximal irradiance.

Light Source Types:

LED (Light-Emitting Diode): Most common modern source; specific blue wavelengths (450-470 nm); long life, minimal heat, energy efficient.

Fluorescent (Special Blue): Traditional source; broader spectrum; generates more heat; shorter lamp life.

Halogen/Tungsten: Older technology; less efficient; high heat output; largely obsolete.

Fiberoptic: Light generated remotely and transmitted through fiber optic cable to illuminated pad.

Spectral Output: Peak wavelength typically 450-470 nm (blue spectrum optimal for bilirubin absorption).

Irradiance: Measured in µW/cm²/nm at skin level (typical range: 10-50+ µW/cm²/nm).

Treatment Surface Area: Size of illuminated area (varies by device type).

2. TECHNICAL & PERFORMANCE PROPERTIES

Peak Wavelength: 450-470 nm (optimal for bilirubin absorption). Narrow spectrum LEDs provide targeted therapy with minimal unnecessary light.

Irradiance Output: 10-50+ µW/cm²/nm at specified distance (intensive units ≥30 µW/cm²/nm).

Spectral Width: Half-peak bandwidth typically 20-40 nm (narrower is more efficient).

Treatment Area Coverage: Overhead units: 30-60 cm × 20-40 cm; Fiberoptic pads: 10-25 cm × 15-30 cm.

Irradiance Uniformity: ±20% variation across treatment areas (meets international standards).

Warm-Up Time: LED units: instant; Fluorescent: 1-5 minutes.

Lamp Life: LED: 10,000-50,000 hours; Fluorescent: 1,000-2,000 hours.

Heat Output: LED: minimal; Fluorescent: significant (requires ventilation).

Timer: Built-in hour meter for tracking lamp life and treatment duration.

Alarms: Some units include alarms for fan failure, lamp failure, or excessive temperature.

Adjustability: Height adjustment for overhead units; flexible positioning arms.

3. PHYSICAL & OPERATIONAL PROPERTIES

Overhead Phototherapy Units:

Configuration: Mobile stand with adjustable height arm and lamp head.

Lamp Head: Contains LED array or fluorescent lamps with reflector.

Controls: On/off, timer, irradiance settings (if adjustable).

Dimensions (Head): 30-60 cm × 20-40 cm.

Height Range: Adjustable from 100-180 cm from floor.

Casters: Locking casters for mobility and stability.

Fiberoptic Phototherapy Systems (Biliblanket):

Light Source Console: Generates light; contains lamp and cooling fan.

Fiberoptic Cable: Flexible cable transmitting light to pad.

**Illuminated Pad/Pad: Flexible, washable pad emitting light; placed against infant's skin.

Console Dimensions: 20-30 cm × 15-25 cm × 10-20 cm.

Pad Dimensions: 10-25 cm × 15-30 cm.

Weight: 3-8 kg (console).

LED Phototherapy Units:

Configuration: Mobile or fixed; may be overhead or under-bed (bassinet) type.

LED Array: Multiple high-intensity LEDs with specific wavelength.

Cooling: Passive or fan-cooled; minimal heat output.

Controls: Digital display, timer, irradiance adjustment.

Material: Medical-grade plastic housing; easy-clean surfaces.

Power Requirements: 100-240 VAC, 50/60 Hz.

Certifications: Complies with relevant medical device standards (IEC 60601-2-50 for phototherapy equipment).

4. SAFETY & COMPLIANCE ATTRIBUTES

Regulatory Status: Class II medical device requiring FDA 510(k) clearance; CE marked.

Clinical Standards: Complies with IEC 60601-2-50 (particular requirements for infant phototherapy equipment).

Optical Safety: UV emission must be minimal (<0.001 mW/cm²); blue light exposure within safe limits for neonatal retina (AAP guidelines).

Thermal Safety: Surface temperatures limited to prevent burns; overheating protection.

Electrical Safety: Compliant with IEC 60601-1 for medical electrical equipment.

Mechanical Safety: Stable base prevents tipping; secure cord management.

Irradiance Measurement: Built-in or accessory irradiance meter for verifying treatment dose.

Lamp Life Indicator: Hour meter or timer to track lamp replacement needs.